Patients with IDA with a history of unsatisfactory oral iron therapy appear to benefit from treatment with IV ferumoxytol.
The oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has an "unprecedented single agent overall response rate" in patients with relapsed or refractory mantle cell lymphoma (MCL), interim results of a global phase 2 study reported during the 54th American Society of Hematology Annual Meeting and Exposition.
The combination of the investigational weekly oral, proteasome inhibitor, MNL9708, plus standard dose lenalidomide and dexamethasone has antitumor activity at the recommended phase 2 dose in treatment-naïve patients with multiple myeloma, investigators reported at the 54th American Society of Hematology Annual Meeting and Exposition.
Asparaginase Erwinia chrysanthemi (marketed as Erwinaze) is well tolerated among children and young adults diagnosed with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to the Escherichia coli-derived L-asparaginase (L-ASP), according to compassionate use protocol data presented during the 54th American Society of Hematology Annual Meeting and Exposition. L-ASP is part of standard chemotherapy regimens for ALL.
Adding aspirin therapy to FCR (fludarabine, cyclophosphamide and rituximab) improves outcomes for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to a single-institution study presented during the 54th American Society of Hematology Annual Meeting and Exposition.
This article reviews the most significant research on prostate cancer presented last month at ASCO 2012, with commentary from Dr Neal Shore.
Initial salvage treatment with allogenic stem cell transplant (ASCT) is feasible and yields superior outcomes to salvage chemotherapy in acute myeloid leukemia (AML) patients.
Abiraterone acetate (AA) plus prednisone (P) produced a statistically significant improvement in radiographic progression-free survival (rPFS) and a strong trend for increased overall survival (OS), according to the results of a study presented by a multinational team of researchers at the 2012 American Society of Clinical Oncology Annual Meeting.
Dr. Barbara Burtness is a physician-scientist of the Fox Chase Cancer Center and an expert in the treatment of head and neck cancer.
Maintenance chemotherapy with the combination of gemcitabine and paclitaxel (GP) following clinical response to GP is associated with improved survival times.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|